AGM Statement

Alderley Park, 9 July 2025 - TheraCryf plc (AIM: TCF), the clinical stage drug development company focussing on brain disorders, will be holding its Annual General Meeting at 2:30pm BST today at The Royal Society of Medicine, 1 Wimpole St, London, W1G 0AE.

At the AGM, TheraCryf's Chair, Dr Alastair Smith; CEO, Dr Huw Jones; CFO, Toni Haenninen and CBO, Dr Helen Kuhlman will give the following operational update to shareholders:

Ox-1

Lead asset Ox-1, TheraCryf's orexin 1 antagonist in addictive behaviours, continues to make good progress following the fundraising in March of this year to fund the programme to clinical readiness. Having appointed leading contract research and manufacturing organisation, Pharmaron UK, as partner, their team are currently working on optimising the synthesis of Ox-1 in order to scale up to produce the kilogram quantities required for regulatory standard toxicology work and later, clinical studies.

The Ox-1 molecule has been shown to be highly stable at room temperature. An archive sample produced by Chronos Therapeutics Ltd in 2020, tested at Pharmaron, was found to have greater than 99% purity. This potential for long-term stability, which will be confirmed with additional stability testing of the newly produced material, will be an important factor in achieving optimal commercial potential. The chemistry and biology work are progressing well with testing underway to understand further characteristics of Ox-1's synthesis and activity.

Additional in vitro testing indicates that Ox-1 is well handled in cells from a new, fourth species, which will be essential to confirm its toxicology profile, a key enabling study before eventual permission to administer the agent to man.

SFX-01

The company's legacy SFX-01 programme also continues to progress with the grant-funded Glioblastoma (GBM) project at the Erasmus Medical Centre in the Netherlands confirming that drug from SFX-01 crosses the blood-brain barrier in in vivo experiments, essential for GBM brain tumour treatment.

An academic collaboration in the USA on colorectal cancer has also reported data showing that Nrf2, a known molecular target, is up-regulated by SFX-01 only in diseased colon cancer models and not where the disease is absent.

Further, collaborating teams from Queen Mary University of London, Barts Hospital, Imperial College London, UCL, University of Oxford and University of Leicester have had a scientific paper on the effects of SFX-01 on another molecular target, SHP-2, accepted by a peer-reviewed journal which will be published imminently.

Dr Huw Jones, CEO of TheraCryf commented:

"We are pleased with how our Ox-1 programme is developing on-time and to-plan as we complete the final steps for readiness for human trials. Our commercial and academic collaborations are continuing to generate insightful data. We would like to thank our shareholders for their continued support as we unlock value from our assets."